Physician profile
Amy Sue Warner
NPI 1962598912
$2,831.50
in general payments reported to CMS, 2019-2025
28 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $188 · 2021: $549 · 2022: $772 · 2023: $264 · 2024: $92.70 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.69 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $323.00 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.20 | 2019-2023 | Jardiance |
| Amgen INC. | $187.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $182.16 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $170.48 | 2019-2023 | |
| Lilly USA, LLC | $168.62 | 2022-2024 | Trulicity, Mounjaro, Jardiance |
| Scpharmaceuticals INC. | $121.86 | 2025 | |
| Abbvie INC. | $108.09 | 2019-2023 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $102.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $93.43 | 2019-2022 | |
| Amarin Pharma, INC. | $91.53 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.85 | 2022-2023 | |
| Abbott Laboratories | $86.98 | 2021-2025 | Freestyle Libre 3 |
| Avanos Medical | $82.74 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $61.65 | 2022-2023 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $50.19 | 2021 | |
| Boston Scientific Corporation | $35.72 | 2021 | |
| Medtronic, INC. | $32.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.12 | 2021 | |
| Genentech USA, INC. | $24.88 | 2019 | |
| Radius Health, INC. | $22.34 | 2019 | |
| Nevro Corp. | $20.33 | 2021 | |
| Hologic Sales and Service, LLC | $18.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.67 | 2024 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $17.51 | 2019 | |
| Nabriva Therapeutics, Plc | $11.94 | 2021 | |
| Allergan, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.